New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy
- 195 Downloads
New gene expressed in prostate (NGEP) is a prostate-specific gene encoding either a small cytoplasmic protein (NGEP-S) or a larger polytopic membrane protein (NGEP-L). NGEP-L expression is detectable only in prostate cancer, benign prostatic hyperplasia and normal prostate. We have identified an HLA-A2 binding NGEP epitope (designated P703) which was used to generate T cell lines from several patients with localized and metastatic prostate cancer. These T cell lines were able to specifically lyse HLA-A2 and NGEP-expressing human tumor cells. NGEP-P703 tetramer binding assays demonstrated that metastatic prostate cancer patients had a higher frequency of NGEP-specific T cells when compared with healthy donors. Moreover, an increased frequency of NGEP-specific T cells was detected in the peripheral blood mononuclear cells of prostate cancer patients post-vaccination with a PSA-based vaccine, further indicating the immunogenicity of NGEP. These studies thus identify NGEP as a potential target for T cell-mediated immunotherapy of prostate cancer.
KeywordsNGEP Prostate cancer T cell Vaccine Epitopes
Cytotoxic T lymphocytes
Epstein Barr virus
Expressed sequence tag
Human leukocyte antigen-A2 allele
In vitro stimulation
Mean fluorescence intensity
New gene expressed in prostate
Peripheral blood mononuclear cells
Triad of costimulatory molecules (B7.1, ICAM-1, LFA-3)
The authors thank Bonnie Casey and Debra Weingarten for their editorial assistance in the preparation of this manuscript. This research was supported by the Intramural Research Program of the Center for Cancer Research, NCI, NIH.
Conflict of interest statement
There are no potential conflicts of interest.
- 3.Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, Beetham P, Tsang KY, Grosenbach DW, Feldman J, Steinberg SM, Jones E, Chen C, Marte J, Schlom J, Dahut W (2006) A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 12:1260–1269CrossRefPubMedGoogle Scholar
- 4.Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, Tsang KY, Yokokawa J, Hodge JW, Menard C, Camphausen K, Coleman CN, Sullivan F, Steinberg SM, Schlom J, Dahut W (2005) Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 11:3353–3362CrossRefPubMedGoogle Scholar
- 11.Kiessling A, Schmitz M, Stevanovic S, Weigle B, Holig K, Fussel M, Fussel S, Meye A, Wirth MP, Rieber EP (2002) Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients. Int J Cancer 102:390–397CrossRefPubMedGoogle Scholar
- 15.Taira A, Merrick G, Wallner K, Dattoli M (2007) Reviving the acid phosphatase test for prostate cancer. Oncology (Williston Park) 21:1003–1010Google Scholar
- 30.Lattouf JB, Arlen PM, Pinto PA, Gulley JL (2006) A phase I feasibility study of an intraprostatic prostate-specific antigen-based vaccine in patients with prostate cancer with local failure after radiation therapy or clinical progression on androgen-deprivation therapy in the absence of local definitive therapy. Clin Genitourin Cancer 5:89–92CrossRefPubMedGoogle Scholar